Biogen and Novartis may have walked away from partnerships with Sangamo Therapeutics last year, but that hasn't stopped Roche ...

Big Pharmas remain stuck to the idea of molecular glue degraders. | Big Pharmas remain stuck to the idea of molecular glue ...

Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by ...

Asset manager TPG, which has supported biotechs such as Sionna Therapeutics and Santa Ana Bio, has topped up its Life Science ...

Ultimovacs’ cancer vaccine UV1 has failed yet another midphase clinical trial. The third flop, this time in head and neck ...

After BioMarin conducted a spring clean of its pipeline in April, the company has decided that it also needs to offload a ...

Levicept arose from the metaphorical ashes of Pfizer’s former R&D campus in the U.K. Now, the biotech has scored a phase 2 ...

Full-service contract research organization Rho has named neurologist Andrew Feigin, M.D., its new chief medical officer. Feigin is an expert in movement disorders such as Parkinson’s disease. | ...

Neuralink has implanted its device in a second patient, according to the startup's owner Elon Musk. | Neuralink has implanted its device in a second patient, according to the startup's owner Elon Musk ...

Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos, to CVC Capital Partners for $925 ...

A new global life science credit firm, dubbed Symbiotic Capital, has raised more than $600 million. | A new global life science credit firm, dubbed Symbiotic Capital, has raised more than $600 million ...

Three years since founding Site Alliance in 2021, Genentech is now sharing data showing sites in the alliance enroll more ...